U.S. markets close in 5 hours 31 minutes

Mind Medicine (MindMed) Inc. (MNMD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.5900-0.0100 (-0.28%)
As of 10:29AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close3.6000
Open3.6000
Bid3.5900 x 3000
Ask3.6000 x 4000
Day's Range3.5600 - 3.6800
52 Week Range0.3000 - 5.7700
Volume1,440,456
Avg. Volume9,114,232
Market Cap820.171M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board
    CNW Group

    MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board

    MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Peter Bergethon, a world-leading expert in neurology, digital medicine, and central nervous system (CNS) drug development to the Company's Scientific Advisory Board.

  • “The Science Behind Using Psychedelics To Treat Mental Health Disorders And Addiction Is Compelling”
    GlobeNewswire

    “The Science Behind Using Psychedelics To Treat Mental Health Disorders And Addiction Is Compelling”

    Jim Cramer discussed psychedelics on his June 15, 2021 program and said big drug companies tried, and failed, to treat major depression. Here are four psychedelic companies you need to know about that are addressing the mental health crisis.OTCStockReview.com News Commentary ATLANTA, June 16, 2021 (GLOBE NEWSWIRE) -- Jim Cramer discussed psychedelics on his June 15, 2021 program and said, “The science behind using psychedelics to treat mental health disorders and addiction is compelling." He als

  • MindMed Announces Chief Executive Officer Transition
    PR Newswire

    MindMed Announces Chief Executive Officer Transition

    Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Rahn, the Company's co-founder and chief executive officer, is stepping down as chief executive officer and a director, and that its chief development officer, Robert Barrow, will assume the position of chief executive officer with immediate effect. The Company will also initiate a comp